Congress Materials

Medical Information
Ireland
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a healthcare professionalYes, I am a healthcare professional
SelectI am a healthcare professionalYes, I am a healthcare professional
I am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal
SelectI am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal

If you don't reside in Ireland, please click here

The medical information on this site is intended only for healthcare professionals in the Republic of Ireland. The products discussed herein may have different product labeling in other countries.

This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Tripathy D, Blum JL, Sleckman B, Patel K, Nakhoul I, Gauthier E, Montelongo MZ, Zhang Z, Wang Y, Rocque G December 7, 2022 SABCS 2022 Oncology

Characterization of Neutropenia in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) on Palbociclib in a Real-World Setting: Results From POLARIS

View Presentation View Abstract Plain Language Summary
Poster
Rocque G, Blum JL, Specht J, Dul C, Corso S, Cuevas D, Gauthier E, Montelongo MZ, Zhang Z, Wang Y, Tripathy D December 7, 2022 SABCS 2022 Oncology

Laboratory Monitoring in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer Treated with Palbociclib in a Real-World Setting: Results From POLARIS

View Presentation View Abstract Plain Language Summary
Poster
Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A December 7, 2022 SABCS 2022 Oncology

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer

View Presentation View Abstract Plain Language Summary
Poster
Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A December 7, 2022 SABCS 2022 Oncology

Real-World Treatment Patterns of Palbociclib Plus an Aromatase Inhibitor or Aromatase Inhibitor Alone for Metastatic Breast Cancer in the Flatiron Database

View Presentation View Abstract Plain Language Summary
Poster
Tripathy D, Blum JL, Deng S, McCune SL, Patel K, Wang Y, Lakhanpal S, Karuturi MS, Zhang Z, Deshpande C, Montelongo MZ, Gauthier E, Liu Y, Rocque GB, Bardia A December 8, 2022 SABCS 2022 Oncology

Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving the Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib: Biomarker Results From POLARIS

View Presentation View Abstract Plain Language Summary
Poster
Brufsky A, Maculaitis MC, Kopenhafer L, Olsen P, Cha AS, Arruda LS, Heck W, Kurosky SK December 8, 2022 SABCS 2022 Oncology

Identifying Drivers of First-Line HR+/HER2- Metastatic Breast Cancer Treatment Choices

View Presentation View Abstract Plain Language Summary
Poster
Ueno T, Chow LWC, Han W, Huang CS, Mann GB, Morita S, Haga H, Fakhrejahani E, Kobayashi T, Bando H, Inoue K, Tokiwa M, Suwa H, Aruga T, Minamiguchi S, Yamada Y, Tanabe Y, Takada M, Yamashita T, Iwata H, Chun C-F, Takahara S, Tokunaga E, Imoto S, Lee ES, Sagara Y, Kim JH, DeBoer RH, Kim H-A, Lai HW, Hou MF, White M, Umeyama Y, Toi M December 8, 2022 SABCS 2022 Oncology

Neoadjuvant Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

View Presentation
Oral Presentation
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Jolly T, Riley E, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block C, Ko N, Partridge AH, Chen W, DeMeo M, Attaya V, Okpoebo A, Liu Y, Gauthier E, Burstein HJ, Regan M, Tolaney SM December 8, 2022 SABCS 2022 Oncology

PACE: Palbociclib After CDK and Endocrine Therapy A Randomized Phase II Study of Fulvestrant +/ Palbociclib after Progression on CDK4/6 inhibitor for HR+/HER2 Metastatic Breast Cancer

View Presentation
Poster
Karadurmus N, Sendur MAN, Cil T, Oksuzoglu OBC, Arslan C, Harputluoglu H, Gosku SS, Ozturk B, Inanc M, Cubukcu E, Demirci U, Erdem D, Cihan S, Tural D, Dumludag A, Aykan MB, Yilmaz F, Avsar E, Sonusen SD, Ozturk OF, Aver B, Kaplan MA December 8, 2022 SABCS 2022 Oncology

Patient and Treatment Characteristics in HR+/HER2- Metastatic Breast Cancer in a Real-Life Setting

View Presentation
Poster
Loirat D, de Labarre MD, Villanueva C, Mailliez A, Isambert N, Moreau L, Jacquet E, Spaëth D, Creisson A, Jouannaud C, Legouffe E, Delbado M, Deiana L, Soibinet P, Hrab I, Grellety T, Dohollou N, Longo R, Thery J-C, Fumet J-D, Zineb S, Bragado A, Decrop M, De La Motte Rouge T, Pujol P December 8, 2022 SABCS 2022 Oncology

Phase IV Multicenter Study Evaluating RWE and the Safety of Talazoparib in Patients with Locally Advanced or Metastatic Negative HER2 Breast Cancer and a BRCA1/2 Mutation (ViTAL) - Cohort 2: Patients Treated According to the EMA

View Presentation